Multiple Myeloma

Multiple Myeloma

Indatuximab Ravtansine Has Encouraging Activity in Relapsed/Refractory Multiple Myeloma

Indatuximab ravtansine with lenalidomide or pomalidomide shows encouraging clinical activity for R/R MM, according to data from a phase 1/2a study published in the Lancet Haematology.

Hematology Advisor
MiR-22 Mimics With Lenalidomide Help Inhibit MYC Expression, Improve Drug Resistance in Multiple Myeloma

Lenalidomide combined with miR-22 mimics may sensitize multiple myeloma cells to help overcome drug resistance, according to research published in Cancers.  

Hematology Advisor
IR-neoAg Load Predicts Prognosis in Both Newly Diagnosed and Relapsed Multiple Myeloma

Among patients with multiple myeloma, IR-neoAg load may predict prognosis, according to research published in Oncogene.

Hematology Advisor

Does Ethnicity Matter in Multiple Myeloma Risk Prediction in the Era of Genomics and Novel Agents?

The impact of ethnicity in MM risk prediction is explored and an efficient and robust AI-enabled risk-stratification system for NDMM patients utilizing ethnicity-specific cutoffs is developed. 

Frontiers in Oncology
COVID-19 Vaccination in Patients With Multiple Myeloma: A Consensus of the European Myeloma Network

Available data in patients with MM suggest a suboptimal anti-SARS-CoV-2 immune response, meaning a proportion of patients are unprotected, and at risk for infection with SARS-CoV-2 virus.

The Lancet Hematology
Combination Melflufen, Dexamethasone, Bortezomib Appears Safe in Patients With Multiple Myeloma

For RRMM patients with poor prognostic factors, a triplet regimen of melflufen, dexamethasone, and bortezomib is well-tolerated, according to a trial presented at the 2021 LL&M Congress.

Hematology Advisor
Oncopeptides Withdraws Multiple Myeloma Therapy From U.S. Market

The decision came 3 months after the FDA alerted health care providers and patients about clinical trial results that showed increased mortality risk among patients who received the agent.

Combined Immune Score Predicts the Prognosis of Newly Diagnosed Multiple Myeloma Patients in the Bortezomib-Based Therapy Era

This study investigated the effect of a combined immune score including the lymphocyte-to-monocyte ratio and uninvolved immunoglobulin levels on the prognosis of newly diagnosed multiple myeloma...

Younger Age at Diagnosis May Predict Higher VTE Risk in Patients With Multiple Myeloma

Among younger patients with multiple myeloma and those with a high white cell count, higher-intensity thromboprophylaxis may be necessary for reducing the risk of venous thromboembolism.

Cancer Therapy Advisor
Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone Alone in Newly Diagnosed Multiple Myeloma

A significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone...

The Lancet Oncology
Salvage Autologous Stem Cell Transplantation May Improve Outcomes for Relapsed/Refractory Multiple Myeloma

Salvage therapy with high-dose chemotherapy followed by ASCT may lead to long-term improvements in survival for MM in some patients.

Hematology Advisor
Effect of EPA on Hsp90 and GRα Protein Expression in Multiple Myeloma Drug-Resistant Cells

Scientists test the cytotoxic effects of EPA alone or EPA + Dexamethasone in MM.1R and investigate whether DHA can induce apoptosis and reverse acquired glucocorticoid resistance in MM.1R.

BMC Cancer
Comparison Between Tumour Metabolism Derived from 18F-FDG PET/CT and Accurate Cytogenetic Stratification in Newly Diagnosed Multiple Myeloma Patients

This study examines the correlation between the new LP score and PET data among patients newly diagnosed for MM or secreting plasmacytoma...

Quantitative Imaging in Medicine and Surgery
Tissue-Resident Macrophages Promote Early Dissemination of Multiple Myeloma via IL-6 and TNFα

Researchers propose that egress of myeloma cells from BM is regulated by localized inflammation in foci, driven in part by CD169+ MPs.

Blood Advances
Pathophysiological Role of Calcium Channels and Transporters in the Multiple Myeloma

Research summarizes the expression, localization and pathophysiological role of some essential calcium channels and transporters...

Cell Communication and Signaling
Maintenance Daratumumab After Initial Therapy for Newly Diagnosed Multiple Myeloma

Scientists significantly prolonged progression-free survival with maintenance daratumumab vs observation following induction and consolidation with or without daratumumab in addition to ASCT...

The ASCO Post
Single Cell RNA-seq Data and Bulk Gene Profiles Reveal a Novel Signature of Disease Progression in Multiple Myeloma

Scientists complete a comprehensive analysis of scRNA-seq data and bulk gene expression profiles to reveal the development map of human MM cells...

Cancer Cell International
Prognostic Importance of Extramedullary Lesions in Multiple Myeloma

Researchers conducting a retrospective study identified extramedullary lesions as a possible indicator of poor prognosis in patients with MM treated in the first line with bortezomib. 

Cancer Therapy Advisor
Targeting The Methyltransferase SETD8 Impairs Tumor Cell Survival and Overcomes Drug Resistance Independently of p53 Status in Multiple Myeloma

Investigators showed that SETD8 inhibition is strongly synergistic with melphalan and may overcome resistance to this alkylating agent widely used in MM treatment.

Clinical Epigenetics
Subcutaneous Daratumumab Added to Pomalidomide Plus Dexamethasone Improves Progression-Free Survival in Multiple Myeloma

The phase III APOLLO trial has shown significantly improved PFS with the addition of subcutaneous daratumumab to oral pomalidomide/dexamethasone in previously treated MM.

The ASCO Post
Updated Safety and Efficacy of CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

A single dose of ciltacabtagene autoleucel yields early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Cancer Therapy Advisor
How Prior Alkylator Exposure Impacts the Efficacy of Melflufen in Multiple Myeloma

Results of a pooled analysis suggest that melflufen plus dexamethasone is active in patients with relapsed or refractory multiple myeloma who were exposed to prior alkylators.

Cancer Therapy Advisor
Microparticles and PD1 Interplay Added a Prognostic Impact in Treatment Outcomes of Patients With Multiple Myeloma

Study investigators examine the expression of PD1 and different microparticles in MM and their interplay as a mechanism of resistance to standardized treatments...

Scientific Reports
Role of Whole-Body Diffusion-Weighted Imaging in Evaluation of Multiple Myeloma

This study retrospectively investigates whole-body diffusion-weighted imaging in the evaluation of bone marrow infiltration and treatment response in multiple myeloma.

Addition of Venetoclax to Daratumumab/Dexamethasone With or Without Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Investigators find that venetoclax plus daratumumab/dexamethasone and VenDd with bortezomib produce high rates of durable responses in patients with R/R MM with...

The ASCO Post
Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma

Immunotherapy based on CAR-T therapy has achieved success in the treatment of hematological malignant tumors. Investigators successfully constructed two novel second-generation...

Frontiers in Oncology
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

This phase I study evaluates venetoclax with daratumumab and dexamethasone in patients with t(11;14) RRMM and VenDd with bortezomib in cytogenetically unselected patients with RRMM.

Journal of Clinical Oncology
Teclistamab Shows Efficacy, Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Study investigators find that the BCMA-CD3 bispecific antibody teclistamab produces a high rate of durable responses at the recommended phase II dose in patients with R/R MM.

The ASCO Post
Bispecific Antibodies Advance in Relapsed or Refractory Multiple Myeloma

Early clinical trials data suggest bispecific antibodies may help meet this need, as suggested by studies presented at the 2021 ASCO Annual Meeting for talquetamab, teclistamab, and elranatamab.

The ASCO Post
BCMA-Directed CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma

In the phase Ib/II CARTITUDE-1 trial reported in The Lancet, Dr Berdeja and colleagues found that ciltacabtagene autoleucel produced a high rate of durable and deep responses...

The ASCO Post
Study Finds Response to COVID-19 Vaccination Varies Widely in Patients With Multiple Myeloma

Patients with MM had a wide variety of responses to COVID-19 vaccines—in some cases, no detectable response at all—pointing to the need for antibody testing and precautions...

The ASCO Post
Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression

Study investigators define incidence and risk factors of ONJ and explore oral microbial signatures and host immune response as reflected by cytokine changes in saliva and serum in MM patients...

Frontiers in Oncology
SMAD1 as a Biomarker and Potential Therapeutic Target in Drug-Resistant Multiple Myeloma

Study investigators aim to examine if SMAD1 plays an important role in multiple myeloma pathogenesis and can serve as a therapeutic target.

Biomarker Research

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(235, 64, 52)